Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUPAS31532 | Registry Identifier | EU PAS Register |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Abatacept Group | Participants with established rheumatoid arthritis (RA) or psoriatic arthritis (PsA) and receiving abatacept | ||
| Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group | Participants with established RA or PsA and not previously treated with any targeted disease modifying anti-rheumatic drugs (DMARDs) and who start treatment with a non-targeted DMARD | ||
| Targeted DMARD Group | Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence Rates of Overall Malignancies | Up to 5 years | |
| Incidence Rates of Melanoma | Up to 5 years | |
| Incidence Rates of Non-melanoma Skin Cancer | Up to 5 years | |
| Incidence Rates of Basal Cell Carcinoma | Up to 5 years | |
| Incidence Rates of Squamous Cell Carcinoma | Up to 5 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
-Not applicable
Not provided
Not provided
Not provided
Adult participants with RA or PsA who are enrolled in the Danish Database for Biologic Therapies (DANBIO) register in Denmark and were receiving abatacept, non-targeted DMARDs, or targeted DMARDs between January 2007 and December 2021.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution - 0001 | Lawrenceville | New Jersey | 08543 | United States |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D015535 | Arthritis, Psoriatic |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D011565 | Psoriasis |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |